导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.38% | 1847/4773 |
| 近一周 | -2.01% | 3263/5465 |
| 近一月 | -4.20% | 3101/5421 |
| 近一季 | -5.81% | 2184/5231 |
| 近半年 | 0.32% | 1322/4920 |
| 近一年 | 6.83% | 1550/4394 |
| 近两年 | 54.99% | 1366/2954 |
| 近三年 | 38.17% | 807/2253 |
| 成立以来 | 164.43% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.81% 2916/4961 |
15.54% 1659/5312 |
- - |
- - |
| 2025 | 24.07% 1813/4813 |
1.04% 1712/3635 |
1.44% 2331/4076 |
20.03% 2052/4524 |
0.85% 1721/4813 |
| 2024 | 16.72% 773/3463 |
3.11% 621/2808 |
-0.59% 793/3014 |
17.11% 1276/3129 |
-2.76% 2178/3463 |
| 2023 | -8.15% 982/2656 |
4.54% 927/2280 |
-4.05% 1024/2385 |
-2.29% 656/2515 |
-6.28% 1704/2655 |
| 2022 | -18.22% 678/2207 |
-12.84% 661/1919 |
7.36% 491/2016 |
-14.07% 1018/2113 |
1.70% 1175/2208 |
| 2021 | -1.45% 800/1822 |
-1.69% 532/1255 |
3.32% 975/1330 |
-4.84% 741/1466 |
1.97% 735/1822 |
| 2020 | 39.75% 324/1250 |
-8.32% 600/1028 |
13.42% 620/1067 |
15.56% 208/1164 |
16.30% 180/1184 |
| 2019 | 46.45% 135/1092 |
25.04% 481/754 |
3.86% 43/804 |
4.95% 171/850 |
7.45% 431/918 |
| 2018 | -18.20% 139/834 |
- - |
- - |
- - |
-11.73% 341/691 |
| 2017 | 34.04% 42/714 |
- - |
- - |
- - |
- - |
| 2016 | -3.84% 149/605 |
- - |
- - |
- - |
- - |
| 2015 | -0.09% 256/575 |
- - |
- - |
- - |
- - |
| 2014 | 58.92% 39/237 |
- - |
- - |
- - |
- - |
| 2013 | -8.79% 139/186 |
- - |
- - |
- - |
- - |
| 2012 | 8.25% 58/140 |
- - |
- - |
- - |
- - |
| 2011 | -20.56% 41/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 宝盈中证A100指数增强A VS. 长安沪深300非周期A(740101) |